Business
POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings
LYON, France, January 30, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the discharge from judicial reorganisation proceedings and ratification of the recovery plan by the Commercial Court of Lyon.
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/af44b7b52d042d1e53f545bd576c519e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zd2.GIOBniY8L269tUKN9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/af44b7b52d042d1e53f545bd576c519e","width":480,"height":256}},"lazy":false},{"type":"text","content":"LYON, France, January 30, 2026--(BUSINESS WIRE)--Regulatory News:","length":65,"tagName":"p","attribs":{}},{"type":"text","content":"POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the discharge from judicial reorganisation proceedings and ratification of the recovery plan by the Commercial Court of Lyon.","length":411,"tagName":"p"},{"type":"text","content":"This decision closes the observation period opened on August 5, 2025, confirms the exit of POXEL SA from judicial reorganisation proceedings, and will enable the Company to implement the recovery plan presented to shareholders in several communications issued in November and December 2025.","length":290,"tagName":"p"},{"type":"text","content":"Nicolas Trouche, Chief Executive Officer of Poxel, comments: "This approval by the Commercial Court of Lyon approves the recovery plan prepared by the Company and its creditors during the observation period is an outstanding news. Such approval enables the company to fast-track its commercial development while assuming the settlement of its liabilities. We would like to particularly thank Poxel’s shareholders for their confidence, demonstrated by their vote at the last general meeting in favor of the resolutions necessary to implement the plan, as well as the support of creditors who financed the observation period and confirmed their contributions to secure Poxel’s future."","length":693,"tagName":"p"},{"type":"text","content":"Key Elements of the Recovery plan","length":33,"tagName":"p"},{"type":"text","content":"Business Development","length":20,"tagName":"p"},{"type":"list","items":[{"val":[...